Found: 167
Select item for more details and to access through your institution.
Resmetirom: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 6, p. 729, doi. 10.1007/s40265-024-02045-0
- By:
- Publication type:
- Article
Cefepime/Enmetazobactam: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 6, p. 737, doi. 10.1007/s40265-024-02035-2
- By:
- Publication type:
- Article
Lifileucel: First Approval.
- Published in:
- Molecular Diagnosis & Therapy, 2024, v. 28, n. 3, p. 339, doi. 10.1007/s40291-024-00708-y
- By:
- Publication type:
- Article
Lebrikizumab: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 3, p. 347, doi. 10.1007/s40265-024-02000-z
- By:
- Publication type:
- Article
Nirogacestat: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 3, p. 355, doi. 10.1007/s40265-024-02002-x
- By:
- Publication type:
- Article
Berdazimer Topical Gel, 10.3%: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 3, p. 363, doi. 10.1007/s40265-024-02012-9
- By:
- Publication type:
- Article
Vamorolone: First Approval.
- Published in:
- Drugs, 2024, v. 84, n. 1, p. 111, doi. 10.1007/s40265-023-01986-2
- By:
- Publication type:
- Article
Cantharidin Topical Solution 0.7%: First Approval.
- Published in:
- Pediatric Drugs, 2024, v. 26, n. 1, p. 95, doi. 10.1007/s40272-023-00600-y
- By:
- Publication type:
- Article
Momelotinib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1709, doi. 10.1007/s40265-023-01964-8
- By:
- Publication type:
- Article
Iruplinalkib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1717, doi. 10.1007/s40265-023-01970-w
- By:
- Publication type:
- Article
Gepirone Extended-Release: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 18, p. 1723, doi. 10.1007/s40265-023-01975-5
- By:
- Publication type:
- Article
Tafolecimab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 16, p. 1545, doi. 10.1007/s40265-023-01952-y
- By:
- Publication type:
- Article
Equecabtagene Autoleucel: First Approval.
- Published in:
- Molecular Diagnosis & Therapy, 2023, v. 27, n. 6, p. 781, doi. 10.1007/s40291-023-00673-y
- By:
- Publication type:
- Article
Talquetamab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 15, p. 1439, doi. 10.1007/s40265-023-01945-x
- By:
- Publication type:
- Article
Sovateltide: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1239, doi. 10.1007/s40265-023-01922-4
- By:
- Publication type:
- Article
Sulbactam/Durlobactam: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 13, p. 1245, doi. 10.1007/s40265-023-01920-6
- By:
- Publication type:
- Article
Correction to: Concizumab: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Mirikizumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 1045, doi. 10.1007/s40265-023-01909-1
- By:
- Publication type:
- Article
Concizumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 11, p. 1053, doi. 10.1007/s40265-023-01912-6
- By:
- Publication type:
- Article
Correction to: Efanesoctocog Alfa: First Approval.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
Pitolisant: Pediatric First Approval.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 4, p. 483, doi. 10.1007/s40272-023-00575-w
- By:
- Publication type:
- Article
Trofinetide: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 9, p. 819, doi. 10.1007/s40265-023-01883-8
- By:
- Publication type:
- Article
Efanesoctocog Alfa: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 7, p. 633, doi. 10.1007/s40265-023-01866-9
- By:
- Publication type:
- Article
Tabelecleucel: First Approval.
- Published in:
- Molecular Diagnosis & Therapy, 2023, v. 27, n. 3, p. 425, doi. 10.1007/s40291-023-00648-z
- By:
- Publication type:
- Article
Pirtobrutinib: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 6, p. 547, doi. 10.1007/s40265-023-01860-1
- By:
- Publication type:
- Article
Teplizumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 5, p. 439, doi. 10.1007/s40265-023-01847-y
- By:
- Publication type:
- Article
Ganaxolone in seizures associated with cyclin-dependent kinase-like 5 deficiency disorder: a profile of its use in the USA.
- Published in:
- Drugs & Therapy Perspectives, 2023, v. 39, n. 3, p. 81, doi. 10.1007/s40267-022-00976-w
- By:
- Publication type:
- Article
Nirsevimab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 2, p. 181, doi. 10.1007/s40265-022-01829-6
- By:
- Publication type:
- Article
Rezvilutamide: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 2, p. 189, doi. 10.1007/s40265-022-01831-y
- By:
- Publication type:
- Article
Ozoralizumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 1, p. 87, doi. 10.1007/s40265-022-01821-0
- By:
- Publication type:
- Article
Tremelimumab: First Approval.
- Published in:
- Drugs, 2023, v. 83, n. 1, p. 93, doi. 10.1007/s40265-022-01827-8
- By:
- Publication type:
- Article
Ibrutinib: Pediatric First Approval.
- Published in:
- Pediatric Drugs, 2023, v. 25, n. 1, p. 127, doi. 10.1007/s40272-022-00543-w
- By:
- Publication type:
- Article
Correction to: Valemetostat Tosilate: First Approval.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Dextromethorphan/Bupropion: First Approval.
- Published in:
- CNS Drugs, 2022, v. 36, n. 11, p. 1229, doi. 10.1007/s40263-022-00968-4
- By:
- Publication type:
- Article
Valemetostat Tosilate: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 16, p. 1621, doi. 10.1007/s40265-022-01800-5
- By:
- Publication type:
- Article
Vutrisiran: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 13, p. 1419, doi. 10.1007/s40265-022-01765-5
- By:
- Publication type:
- Article
Eladocagene Exuparvovec: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 13, p. 1427, doi. 10.1007/s40265-022-01775-3
- By:
- Publication type:
- Article
Correction: Tapinarof Cream 1%: First Approval.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Linzagolix: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 12, p. 1317, doi. 10.1007/s40265-022-01753-9
- By:
- Publication type:
- Article
Cadonilimab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 12, p. 1333, doi. 10.1007/s40265-022-01761-9
- By:
- Publication type:
- Article
Correction to: Tapinarof Cream 1%: First Approval.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Tapinarof Cream 1%: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 11, p. 1221, doi. 10.1007/s40265-022-01748-6
- By:
- Publication type:
- Article
Correction to: Mavacamten: First Approval.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Mavacamten: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1127, doi. 10.1007/s40265-022-01739-7
- By:
- Publication type:
- Article
Nemolizumab: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 10, p. 1143, doi. 10.1007/s40265-022-01741-z
- By:
- Publication type:
- Article
Lutetium Lu 177 Vipivotide Tetraxetan: First Approval.
- Published in:
- Molecular Diagnosis & Therapy, 2022, v. 26, n. 4, p. 467, doi. 10.1007/s40291-022-00594-2
- By:
- Publication type:
- Article
Olipudase Alfa: First Approval.
- Published in:
- Drugs, 2022, v. 82, n. 8, p. 941, doi. 10.1007/s40265-022-01727-x
- By:
- Publication type:
- Article
Aumolertinib: A Review in Non-Small Cell Lung Cancer.
- Published in:
- Drugs, 2022, v. 82, n. 5, p. 577, doi. 10.1007/s40265-022-01695-2
- By:
- Publication type:
- Article
Emerging small molecule antivirals may fit neatly into COVID-19 treatment.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 3, p. 112, doi. 10.1007/s40267-022-00897-8
- By:
- Publication type:
- Article
Trilaciclib for the reduction of chemotherapy-induced myelosuppression in the management of extensive-stage small cell lung cancer: a profile of its use.
- Published in:
- Drugs & Therapy Perspectives, 2022, v. 38, n. 2, p. 64, doi. 10.1007/s40267-021-00889-0
- By:
- Publication type:
- Article